Inflix Pharma is involved in the development of specialty products for diabetes care, including sugar substitutes.

Inflix Pharma

Advanced Accelerator Applications focuses on developing and delivering targeted radioligand therapies and precision diagnostic solutions for oncology.

Advanced Accelerator Applications

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

ConvaTec Group Plc

Curium Pharma is involved in the field of nuclear medicine, providing products and services related to radiopharmaceuticals. It focuses on delivering innovation and exceptional service in this sector.

Metric
Company Name	Inflix Pharma	Advanced Accelerator Applications	ConvaTec Group Plc	Curium Pharma
Symbol			CTEC
MSH ID	COM:INFLIXPHARMA	COM:ADACAP	COM:CONVATECGROUP	COM:CURIUMPHARMA
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Consumer Goods	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals	Medical - Instruments & Supplies	Pharmaceuticals
Country	IN	CH	GB	GB
Stage
Employee Count			10.14K
Website	inflixpharma.com	adacap.com	convatecgroup.com	curiumpharma.com
LinkedIn			convatec
Founders

Metric
Market Cap			63.14M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			2.14B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.20B
EBITDA			482.20M
Operating Income			262.70M
Net Income			130.30M
EPS			0.06
Diluted EPS			0.06
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.56
Operating Profit Margin			0.14
EBITDA Margin			0.23
Net Profit Margin			0.07
Return on Equity			0.09
Return on Assets			0.04
Return on Capital Employed			0.09

INFL

COM:INFLIXPHARMA

Inflix Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			189.47
P/B Ratio			3.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			3.56
EV Multiple			13.58

Metric
Days Sales Outstanding
Days Payables Outstanding			257.98
Days Inventory Outstanding			159.32
Operating Cycle			230.09
Cash Conversion Cycle			146.81
Asset Turnover			0.61

Metric
Operating Cash Flow			367.40M
Free Cash Flow			238.20M
Cash Flow to Debt			0.28
Operating Cash Flow/Sales			0.17
Free Cash Flow Yield			0.01

Metric
Cash & Equivalents			97.60M
Accounts Receivable
Inventory			396.10M
Goodwill			1.30B
Debt to Capitalization			0.46
Debt to Assets			0.39
Current Ratio			1.70
Quick Ratio			1.27

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue			0.04
SG&A to Revenue			0.38